In Brief: Lornamead Settles On Lice Claims; DASCA Introduced In House; FDA Warns Supplement Firms
This article was originally published in The Tan Sheet
Executive Summary
Lornamead settles false claims allegations; DASCA bill introduced in House; FDA warns three firms about unapproved drug claims; Actavis expands manufacturing; Valeant defends reputation, Allergan bid; Tom’s Of Maine launches Toddler Training Toothpaste; and FDA to host Nutrition and Supplement Facts labels.
You may also be interested in...
In Brief: Shasun Buys Nuprin, DSM And GSK Earnings, Ad Claims Referred To FTC
Shasun acquires ibuprofen products; DSM predicts nutrition sales will increase; GSK sales fall on supply chain trouble; Nature’s Medicine Associates’ ad referred to FTC; Heinrich co-sponsors designer steroid bill; and AHPA eases botanical identification burden.
In Brief: Nutrition Facts Update, Valeant Sales
FDA to update Nutrition and Supplement Facts labels; Valeant over performs in Q4, 2013; “probiotic” alone is a health claim, ASA; Troxyphen claims need modification, ERSP; and more In Brief.
Tom’s Of Maine Aims To Leverage Adult Sales Via Children’s Products
Tom’s of Maine expands its children’s oral care portfolio with two toothpastes and a fluoride mouth rinse partly with hopes of bringing their parents into the fold as well, an associate brand manager says. The firm also is launching a natural toothbrush.